Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PIII Study of Idebenone Initiated for DMD: Takeda
September 14, 2009
- SymBio Will Go Public When Bendamustine Is Approved
September 7, 2009
- Gov't to Rush to Take Measures against New-Type Flu
September 7, 2009
- Price Settlement Rate as of June Shows Improvement to 80.5%
September 7, 2009
- Treatment Recommended in High-Risk Patients Even If Simple Test Result Is Negative
September 7, 2009
- BUSINESS NEWS IN BRIEF
September 7, 2009
- METI to Promote Healthcare Tourism
September 7, 2009
- Orapenem Fine Granules 10% for Children: Meiji Seika
September 7, 2009
- DPJ to Come to Power with Landslide Victory vs LDP
September 7, 2009
- 11 New Products, 7 APIs Recommended for NHI Price Listing
September 7, 2009
- Basen Recommended for Approval for Prevention of Type 2 Diabetes
September 7, 2009
- Cervarix Recommended for Approval
September 7, 2009
- REGULATORY NEWS IN BRIEF
September 7, 2009
- Takeda to Initiate Additional Trial for Alogliptin
September 7, 2009
- Astellas to Reshuffle Its Drug Discovery Research Functions
September 7, 2009
- Lilly Drops Arzoxifene Based on Initial PIII Data
September 7, 2009
- R&D NEWS IN BRIEF
September 7, 2009
- 8 APIs Recommended for Switching to OTC Status
September 7, 2009
- Olmetec's Brand Value Ranked No. 1 among ARBs: Nielsen, So-Net M3
September 7, 2009
- Generics Are Not the Same as Original Drugs: Hiroshima Pref. Med. Association
September 7, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…